Company Filing History:
Years Active: 2015-2025
Title: James Shanahan: Innovator in Cancer Treatment
Introduction
James Shanahan is a prominent inventor based in Cambridge, MA, known for his significant contributions to the field of cancer treatment. With a total of 11 patents to his name, he has made remarkable strides in developing innovative therapies aimed at improving patient outcomes.
Latest Patents
Shanahan's latest patents focus on biomarkers of METAP2 inhibitors and their applications. One of his notable disclosures relates to modified or polymer conjugated MetAP2 inhibitors. This patent outlines methods for treating or ameliorating symptoms of metabolic dysfunction associated with cancer treatments. Additionally, it describes the administration of a combination of polymer conjugated MetAP2 inhibitors and a second agent to treat cancer symptoms. Another patent emphasizes small molecule or polymer conjugated MetAP2 inhibitors, detailing methods for addressing metabolic dysfunction in patients with diseases such as cancer.
Career Highlights
Throughout his career, James Shanahan has been associated with Syndevrx, Inc., where he has played a crucial role in advancing research and development in cancer therapies. His work has been instrumental in bridging the gap between innovative research and practical applications in clinical settings.
Collaborations
Shanahan has collaborated with notable colleagues, including John S. Petersen and Peter Cornelius, to further enhance the impact of his research. These collaborations have fostered a dynamic environment for innovation and development in the field of cancer treatment.
Conclusion
James Shanahan's contributions to the field of cancer treatment through his innovative patents and collaborations highlight his commitment to improving patient care. His work continues to pave the way for advancements in medical therapies that address critical health challenges.